• ACE2 Activation by Diminazene Aceturate Mitigates Sepsis Car

  2026-07-28

  The reference study demonstrates that pharmacological activation of ACE2 using Diminazene Aceturate protects against sepsis-induced cardiomyopathy in mice. This protective effect operates through the MasR-Sirt1 pathway, promoting mitochondrial biogenesis and reducing cardiac injury, and clarifies a mechanistic link relevant to both sepsis modeling and mitochondrial research.

• Translating CDK4/6 Inhibition: Strategic Advances with PD 03

  2026-07-28

  This thought-leadership article explores the mechanistic depth and translational potential of PD 0332991 (Palbociclib) HCl, a selective CDK4/6 inhibitor. Merging current mechanistic insights, validated protocol strategies, and a clear-eyed view of the competitive research landscape, it offers actionable guidance for translational researchers aiming to leverage robust cell cycle control and antiproliferative effects in Rb-positive cancer models.

• Pexidartinib (PLX3397): Selective CSF1R Inhibitor for Tumor

  2026-07-27

  Pexidartinib (PLX3397) is an ATP-competitive small molecule inhibitor with high selectivity for CSF1R, effectively modulating tumor-associated macrophages and inducing anti-tumor apoptosis. Its nanomolar IC50 in cell-based assays and well-characterized solubility profile make it a powerful reagent for translational oncology and macrophage biology. The compound’s utility is enhanced by robust supporting evidence and optimized protocols for research workflows.

• TMEM16F in Kupffer Cells Controls Liver Inflammation in List

  2026-07-27

  This study demonstrates that TMEM16F expression in liver Kupffer cells is critical for protecting against Listeria monocytogenes infection through plasma membrane repair and regulation of inflammation. The findings clarify the cell-type specificity of TMEM16F’s protective role and link its activity to control of liver immunopathology and metabolism.

• Anlotinib Hydrochloride: Multi-Target TKI for Angiogenesis I

  2026-07-26

  Anlotinib hydrochloride is a potent multi-target tyrosine kinase inhibitor that suppresses angiogenesis by selectively inhibiting VEGFR2, PDGFRβ, and FGFR1. It demonstrates superior efficacy and low cytotoxicity in endothelial cell assays. Benchmark studies confirm its utility in advanced cancer research models.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Advanc

  2026-07-25

  This study demonstrates that intravesical delivery of p21 mRNA encapsulated in lipid nanoparticles restores tumor suppressor function and inhibits tumor growth in bladder cancer models. The findings highlight a clinically compatible, localized mRNA therapy strategy with translational implications for tumor suppressor replacement.

• Anlotinib Hydrochloride: Next-Generation TKI for Advanced An

  2026-07-24

  Explore how Anlotinib hydrochloride, a cutting-edge multi-target tyrosine kinase inhibitor, redefines anti-angiogenic and tumor proliferation research. This article delivers new insight into pharmacokinetics, assay optimization, and translational impact for cancer research workflows.

• Intravesical p21 mRNA-LNPs for Tumor Suppressor Therapy in B

  2026-07-24

  This study demonstrates successful intravesical delivery of p21 mRNA-loaded lipid nanoparticles (LNPs) as a tumor suppressor replacement therapy in bladder cancer models. The approach targets local restoration of p21, overcoming limitations of current treatments and providing a translational path for mRNA-based therapeutics in non-hepatic tumors.

• PD 0332991 (Palbociclib) HCl: Optimizing CDK4/6 Inhibition W

  2026-07-23

  Unlock the full potential of PD 0332991 (Palbociclib) HCl in translational oncology with practical protocol guidance and troubleshooting strategies. This guide integrates cutting-edge mechanistic insights and comparative reference analysis to streamline experimental design and enhance reproducibility.

• RNA Pol II Inhibition Drives Apoptosis Beyond Transcription

  2026-07-23

  Harper et al. (2025) reveal that cell death from RNA Pol II inhibition is not a passive consequence of transcriptional shutdown, but an actively signaled apoptotic response triggered by loss of hypophosphorylated RNA Pol IIA. This discovery reframes the mechanistic understanding of how transcription-targeting therapies induce cell death, with implications for the design and evaluation of antiproliferative agents.

• Dasatinib Monohydrate in CML Research: Protocols & Innovatio

  2026-07-22

  Dasatinib Monohydrate (BMS-354825) empowers chronic myeloid leukemia research by precisely inhibiting both imatinib-resistant and nonmutated BCR-ABL kinases. This guide translates recent breakthroughs—such as NET modulation and kinase signaling insights—into actionable workflows and troubleshooting strategies for advanced translational studies.

• Crizotinib Hydrochloride: Enabling Precision ALK Kinase Inhi

  2026-07-22

  Crizotinib hydrochloride accelerates breakthroughs in cancer biology by empowering researchers to dissect and target oncogenic kinase signaling in advanced, patient-derived tumor models. This guide delivers step-by-step workflow enhancements, troubleshooting strategies, and actionable insights for leveraging Crizotinib in assembloid-based cancer research.

• Dasatinib Monohydrate: Mechanistic Insight to Translational

  2026-07-21

  A strategic deep dive into Dasatinib Monohydrate (BMS-354825) for translational researchers, bridging kinase biology, resistance mechanisms, and the next generation of tumor modeling—highlighting patient-derived assembloid systems and APExBIO’s product leadership.

• AMPK–SQSTM1 Feedback Enhances Antioxidant Defense in Metabol

  2026-07-21

  This study reveals a double-positive feedback loop between AMPK and SQSTM1/p62 under metabolic stress, leading to synergistic activation of both AMPK and NFE2L2/NRF2 antioxidant pathways. The mechanistic insights clarify cellular adaptation to metabolic and oxidative challenges, offering new avenues for targeting tumor survival in nutrient-deprived microenvironments.

• IMPDH Inhibition Suppresses PEDV Replication via Metabolic R

  2026-07-20

  This study demonstrates that porcine epidemic diarrhea virus (PEDV) relies on host inosine monophosphate dehydrogenase (IMPDH)-dependent guanine nucleotide biosynthesis for efficient replication. Both genetic and pharmacological inhibition of IMPDH, particularly with Merimepodib (VX-497), significantly suppress PEDV proliferation, highlighting IMPDH as a promising host-directed antiviral target.

14745 records 1/983 page Next 12345 下5页 Last page